Loading...
The two currently available HIV integrase inhibitors — raltegravir and elvitegravir — share similar resistance profiles, such that resistance to one drug generally confers resistance to the other. However, the investigational, next-generation integrase inhibitor dolutegravir seems to have a distinct resistance profile, retaining significant antiviral activity in patients who have failed raltegravir-based therapy.
In a study supported by the manufacturer of dolutegravir, a research team recently characterized the resistance profile of dolutegravir in 30 raltegravir-resistant clinical isolates obtained from patients on failing raltegravir regimens. Previous data have shown that such isolates generally exhibit one of three genotypic mutation pa…